Digital lifestyle management application (levidex) for empowerment and health behaviour change in early multiple sclerosis – Results of the randomised controlled POWER@MS1 trial
This study failed to meet its primary endpoint and usage of levidex did not differ from dexilev in its effects on inflammatory disease activity or behaviour change in this cohort of pwMS.
Authors
- Björn Meyer (ORCID: https://orcid.org/0000-0003-1100-0260)
- Stefan M. Gold (ORCID: https://orcid.org/0000-0001-5188-4799)
- Nicole Krause (ORCID: https://orcid.org/0000-0001-6681-7054)
- Barbara von Glasenapp (ORCID: https://orcid.org/0000-0002-3820-9059)
- Karin Riemann-Lorenz (ORCID: https://orcid.org/0000-0002-0779-2640)
- Christoph Heesen (ORCID: https://orcid.org/0000-0001-8131-9467)
- Markus van de Loo
- Tim Friede (ORCID: https://orcid.org/0000-0001-5347-7441)
- Herbert Temmes
- Charlotte Schubert (ORCID: https://orcid.org/0000-0002-3132-8231)
- Clemens Warnke (ORCID: https://orcid.org/0000-0002-3510-9255)
- Thomas Asendorf (ORCID: https://orcid.org/0000-0003-1317-2138)
- Klarissa Hanja Stürner (ORCID: https://orcid.org/0000-0003-2199-3315)
- Carlotta Derad (ORCID: https://orcid.org/0000-0001-9542-4647)
- Stephan Schmidt (ORCID: https://orcid.org/0000-0001-6311-1574)
Institutions
- Universität Hamburg (DE)
- Philipps University of Marburg (DE)
- Christian-Albrechts-Universität zu Kiel (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Klinik für Psychosomatik (DE)
- German Centre for Cardiovascular Research (DE)
- Praxis für Humangenetik (DE)
- University Hospital Cologne (DE)
- Franklin University (US)
Publication Details
- Journal
- Multiple Sclerosis Journal
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1177/13524585251356410
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- CSL Behring
- Wellcome Trust
- LivaNova
- Argenx
- Apellis Pharmaceuticals
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Eisai
- Servier
- Ipsen
- Neuraxpharm
- Gemeinsame Bundesausschuss
- Grifols
- Allergan
- Sanofi Genzyme
- Bayer Vital
- Daiichi Sankyo Europe